Non-hormonal therapy of menopausal disorders

Abstract

Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms (VMS) and genitourinary menopausal syndrome (GMS) and has been shown to prevent bone loss and destruction. The risks of MHT vary depending on the type, dose, duration of use, routes of administration, timing of initiation, and use of both estrogen and progestogen. Treatment should be individualized with the selection of the most appropriate MHT drug, dose, composition, route of administration, and duration of use, using the best available evidence to maximize benefits and minimize risks, with periodic reassessment of the benefits and risks of continuing or discontinuing MHT use. However, in the presence of absolute contraindications for its use, it is necessary to search for alternative methods of correction of menopausal disorders. In the framework of this article, we will dwell in more detail on alternative methods of treatment of not local, but mainly systemic manifestations of the climacteric syndrome of CS (vasomotor symptoms, insomnia, emotional lability, as well as anxiety-depressive states). After all, if everything is clear and clear with patients who do not have clear contraindications to MHT, then the question of
the contingent of women with their presence or with the so-called hormonophobia still remains open and controversial. For a long time, the world pharmacological community has been engaged in the development of an alternative, estrogen-imitating method of treatment of climacteric disorders. The key components of these drugs are plant components that mimic the physiological action of estrogens, with the exception of its proliferative component, which provides a wider range of possibilities for eliminating CS symptoms and improving the quality of life in patients with a history of cardiovascular disease (CVD), with hyperproliferative reproductive diseases organs and hormone phobia.